The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.
 
Wenfeng Fang
No Relationships to Disclose
 
Yuanyuan Zhao
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Yaxiong Zhang
No Relationships to Disclose
 
Shaodong Hong
No Relationships to Disclose
 
Yihua Huang
No Relationships to Disclose
 
Hongyun Zhao
No Relationships to Disclose
 
Yunpeng Yang
No Relationships to Disclose
 
Shen Zhao
No Relationships to Disclose
 
Gang Chen
No Relationships to Disclose
 
Huaqiang Zhou
No Relationships to Disclose
 
Yuxiang Ma
No Relationships to Disclose
 
Ningning Zhou
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)